DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

The French development agency AFD renews its support for the Drugs for Neglected Diseases initiative (DNDi) in researching and developing treatments for neglected tropical diseases

Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.

L’Agence française de développement poursuit son soutien à Drugs for Neglected Diseases initiative (DNDi) pour appuyer la recherche et le développement de traitements contre les maladies tropicales négligées

Paris, France – le 18 octobre 2019
Bertrand Walckenaer, Directeur délégué de l’Agence française de développement, a signé, ce jour, avec Dr. Bernard Pécoul, Directeur exécutif de DNDi, un projet d’appui à la recherche et au développement de traitements contre les maladies tropicales négligées. La mise en place d’une stratégie de développement de traitements adaptés, abordables et sûrs est un enjeu majeur à l’échelle internationale : plus d’un milliard de personnes réparties dans 149 pays sont touchées par ces maladies. Le projet est une subvention d’un montant de 8 millions d’euros.

World Health Summit 2019

27-29 October 2019
Berlin, Germany

  • Nathalie Strub-Wourgaft, NTD Director – workshops on sustainable elimination of NTDs and on co-creation and co-ownership of the UHC and SDG agendas
  • Monique Wasunna, Director of the DNDi Africa Regional Office – workshop on co-creation and co-ownership of the UHC and SDG agendas

35th ISCTRC Conference

23-27 September 2019
Abuja, Nigeria

  • Olaf Valverde, T.b. Rhodesiense HAT Leader – presentation on the challenges of active case detection for sleeping sickness elimination
  • Junior Mudji, Investigator – presentation on the evolution of the nutritional status of children enrolled in a fexinidazole study
  • Jose Dinanga, Laboratory Coordinator – presentation on strengthening diagnostic documentation procedures


16-20 September 2019
Liverpool, UK

  • DND– one symposium on cutaneous leishmaniasis and one on mycetoma
  • Nathalie Strub-Wourgaft, NTD Director – panel discussion on the future of research and development, satellite symposium on sleeping sickness

MSF Scientific Days

9-10 May 2019
London, UK

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease
  • Nathalie Strub-Wourgaft, Director NTDs – presentation on registration steps for the new all oral sleeping sickness treatment

R&D Portfolio Update February 2019: DNDi Sleeping sickness programme

Fexinidazole, the first all-oral treatment for both stages of HAT caused by T.b gambiense and DNDi’s first new chemical entity, was recommended by the European Medicines Agency in November and registered in Democratic Republic of Congo (DRC) in December 2018. The Phase II/III study on acoziborole opened new clinical sites in DRC and Guinea.